MX2018010924A - Células efectoras inmunitarias con edición genómica. - Google Patents
Células efectoras inmunitarias con edición genómica.Info
- Publication number
- MX2018010924A MX2018010924A MX2018010924A MX2018010924A MX2018010924A MX 2018010924 A MX2018010924 A MX 2018010924A MX 2018010924 A MX2018010924 A MX 2018010924A MX 2018010924 A MX2018010924 A MX 2018010924A MX 2018010924 A MX2018010924 A MX 2018010924A
- Authority
- MX
- Mexico
- Prior art keywords
- immune effector
- effector cells
- genome edited
- edited immune
- disease
- Prior art date
Links
- 239000012642 immune effector Substances 0.000 title abstract 2
- 229940121354 immunomodulator Drugs 0.000 title abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010061598 Immunodeficiency Diseases 0.000 abstract 1
- 208000029462 Immunodeficiency disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002659 cell therapy Methods 0.000 abstract 1
- 230000007813 immunodeficiency Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4636—Immune checkpoint inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
- A61K39/464453—Wilms tumor 1 [WT1]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y307/00—Hydrolases acting on carbon-carbon bonds (3.7)
- C12Y307/01—Hydrolases acting on carbon-carbon bonds (3.7) in ketonic substances (3.7.1)
- C12Y307/01003—Kynureninase (3.7.1.3)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La invencion proporciona mejores composiciones para terapias con celulas efectoras inmunitarias adoptivas para el tratamiento, la prevencion o la mejora de diversas afecciones que incluyen, de modo no taxativo, cancer, enfermedad infecciosa, enfermedad autoinmune, enfermedad inflamatoria e inmunodeficiencia.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662307245P | 2016-03-11 | 2016-03-11 | |
US201662322604P | 2016-04-14 | 2016-04-14 | |
PCT/US2017/021951 WO2017156484A1 (en) | 2016-03-11 | 2017-03-10 | Genome edited immune effector cells |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018010924A true MX2018010924A (es) | 2019-02-13 |
Family
ID=59789707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018010924A MX2018010924A (es) | 2016-03-11 | 2017-03-10 | Células efectoras inmunitarias con edición genómica. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20190241910A1 (es) |
EP (1) | EP3426690A4 (es) |
JP (1) | JP2019509738A (es) |
KR (2) | KR102386029B1 (es) |
CN (1) | CN109311984A (es) |
AU (1) | AU2017230011A1 (es) |
BR (1) | BR112018068354A2 (es) |
CA (1) | CA3017213A1 (es) |
IL (1) | IL261621A (es) |
MX (1) | MX2018010924A (es) |
RU (1) | RU2018135819A (es) |
SG (1) | SG11201807820PA (es) |
WO (1) | WO2017156484A1 (es) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
WO2015105955A1 (en) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
AU2016333886B2 (en) | 2015-10-05 | 2020-10-08 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene |
EP3756682B8 (en) * | 2015-10-05 | 2022-04-27 | Precision Biosciences, Inc. | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene |
JP7250519B2 (ja) * | 2016-03-23 | 2023-04-03 | ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト (ゲーエムベーハー) | Pd-1及び4-1bbの融合タンパク質 |
US20190161530A1 (en) * | 2016-04-07 | 2019-05-30 | Bluebird Bio, Inc. | Chimeric antigen receptor t cell compositions |
KR102437015B1 (ko) | 2016-04-15 | 2022-08-29 | 메모리얼 슬로안 케터링 캔서 센터 | 유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법 |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
CA3035455A1 (en) * | 2016-09-08 | 2018-03-15 | Bluebird Bio, Inc. | Pd-1 homing endonuclease variants, compositions, and methods of use |
AU2017347854B2 (en) * | 2016-10-27 | 2022-12-08 | Intima Bioscience, Inc. | Viral methods of T cell therapy |
EP3583203B1 (en) | 2017-02-15 | 2023-11-01 | 2seventy bio, Inc. | Donor repair templates multiplex genome editing |
CA3062698A1 (en) * | 2017-05-08 | 2018-11-15 | Precision Biosciences, Inc. | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof |
US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
MX2019013514A (es) | 2017-05-12 | 2020-01-20 | Crispr Therapeutics Ag | Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia. |
CA3067382A1 (en) | 2017-06-15 | 2018-12-20 | The Regents Of The University Of California | Targeted non-viral dna insertions |
US11053484B2 (en) | 2017-06-30 | 2021-07-06 | Precision Biosciences, Inc. | Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene |
SG11202003798TA (en) | 2017-10-27 | 2020-05-28 | Univ California | Targeted replacement of endogenous t cell receptors |
MX2020004541A (es) | 2017-10-30 | 2021-04-12 | Pact Pharma Inc | Edicion de genes de celulas primarias. |
CA3085784A1 (en) | 2017-12-14 | 2019-06-20 | Flodesign Sonics, Inc. | Acoustic transducer driver and controller |
CN110221068B (zh) * | 2018-03-02 | 2020-09-18 | 中国医学科学院基础医学研究所 | 检测Kyn含量的试剂的应用 |
EP3765094A4 (en) | 2018-03-15 | 2021-12-22 | KSQ Therapeutics, Inc. | GENE REGULATION COMPOSITIONS AND METHODS FOR IMPROVING IMMUNOTHERAPY |
CN112334480A (zh) | 2018-04-02 | 2021-02-05 | 派克特制药公司 | 肽-MHC comPACT |
KR102617818B1 (ko) | 2018-04-12 | 2023-12-27 | 프리시젼 바이오사이언시스 인코포레이티드 | 인간 t 세포 수용체 알파 불변 영역 유전자에 대한 특이성을 갖는 최적화된 조작된 뉴클레아제 |
EP3790629A1 (en) | 2018-05-11 | 2021-03-17 | CRISPR Therapeutics AG | Methods and compositions for treating cancer |
CN112384230A (zh) * | 2018-05-14 | 2021-02-19 | 瑟姆巴股份有限公司 | 用于自身免疫障碍的基因编辑 |
US20210207174A1 (en) * | 2018-05-25 | 2021-07-08 | The Regents Of The University Of California | Genetic engineering of endogenous proteins |
CA3109924A1 (en) | 2018-08-24 | 2020-02-27 | Csl Behring Gene Therapy, Inc. | Vector production in serum free media |
WO2020042648A1 (zh) * | 2018-08-28 | 2020-03-05 | 法罗斯疫苗株式会社 | 改进的慢病毒载体 |
SG11202101996QA (en) * | 2018-08-28 | 2021-03-30 | Immunotech Biopharm Co Ltd | Improved therapeutic t cell |
US20210388389A1 (en) * | 2018-10-30 | 2021-12-16 | Yale University | Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells |
US11513113B2 (en) | 2019-02-12 | 2022-11-29 | Pact Pharma, Inc. | Compositions and methods for identification of antigen specific T cells |
AU2020262409A1 (en) * | 2019-04-24 | 2021-12-23 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Wiskott-Aldrich syndrome gene homing endonuclease variants, compositions, and methods of use |
JP2022531185A (ja) | 2019-04-30 | 2022-07-06 | クリスパー セラピューティクス アクチェンゲゼルシャフト | 遺伝子改変t細胞を標的化するcd19を使用するb細胞悪性病変の同種細胞療法 |
WO2021057906A1 (zh) * | 2019-09-25 | 2021-04-01 | 科济生物医药(上海)有限公司 | 表达il-15的免疫效应细胞 |
US11820794B2 (en) * | 2019-11-22 | 2023-11-21 | California Institute Of Technology | Method for robust control of gene expression |
CN115003314A (zh) * | 2019-11-27 | 2022-09-02 | 得克萨斯大学体系董事会 | B细胞的大规模组合car转导和crispr基因编辑 |
CN112980886B (zh) * | 2019-12-02 | 2022-02-22 | 河北森朗生物科技有限公司 | 一种能高效制备且应用安全的嵌合抗原受体t细胞及其制备方法与应用 |
JP2023506184A (ja) | 2019-12-11 | 2023-02-15 | エイ2・バイオセラピューティクス・インコーポレイテッド | Lilrb1ベースのキメラ抗原受容体 |
CN110938656B (zh) * | 2019-12-24 | 2021-12-28 | 中国大熊猫保护研究中心 | 重组表达大熊猫促卵泡生成素的载体、表达系统及制备方法 |
MX2023002104A (es) | 2020-08-20 | 2023-07-10 | A2 Biotherapeutics Inc | Composiciones y métodos para tratar cánceres positivos para egfr. |
AU2021329375A1 (en) | 2020-08-20 | 2023-04-20 | A2 Biotherapeutics, Inc. | Compositions and methods for treating ceacam positive cancers |
JP2023538114A (ja) | 2020-08-20 | 2023-09-06 | エー2 バイオセラピューティクス, インコーポレイテッド | メソテリン陽性がんを治療するための組成物及び方法 |
WO2022104344A2 (en) * | 2020-11-10 | 2022-05-19 | The Board Of Trustees Of The Leland Stanford Junior University | Knock-in of large dna for long-term high genomic expression |
WO2022272259A1 (en) * | 2021-06-23 | 2022-12-29 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Car-t cell therapy for triple negative breast cancer |
CN113481184A (zh) * | 2021-08-06 | 2021-10-08 | 北京大学 | 融合蛋白以及其使用方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5866383A (en) * | 1982-11-30 | 1999-02-02 | The United States Of America As Represented By The Department Of Health And Human Services | In vitro ligation of foreign DNA into large eukaryotic viruses |
US8956828B2 (en) * | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
LT2748201T (lt) * | 2011-08-23 | 2018-02-26 | Roche Glycart Ag | Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė |
PL2855667T3 (pl) * | 2012-05-25 | 2024-03-25 | Cellectis | Sposoby uzyskiwania metodami inżynierii allogenicznych i opornych na immunosupresję limfocytów t do immunoterapii |
ES2714523T3 (es) * | 2012-09-04 | 2019-05-28 | Cellectis | Receptor quimérico de antígenos multicatenario y usos del mismo |
CN105452287A (zh) * | 2013-04-17 | 2016-03-30 | 贝勒医学院 | 免疫抑制性TGF-β信号转换器 |
CA2912375C (en) * | 2013-05-13 | 2023-03-14 | Cellectis | Methods for engineering highly active t cell for immunotherapy |
US10000746B2 (en) * | 2013-05-31 | 2018-06-19 | Cellectis | LAGLIDADG homing endonuclease cleaving the T cell receptor alpha gene and uses thereof |
KR102374379B1 (ko) * | 2014-06-06 | 2022-03-17 | 리제너론 파마슈티칼스 인코포레이티드 | 표적화된 좌를 변형시키는 방법 및 조성물 |
-
2017
- 2017-03-10 EP EP17764250.1A patent/EP3426690A4/en not_active Withdrawn
- 2017-03-10 KR KR1020187029089A patent/KR102386029B1/ko active IP Right Grant
- 2017-03-10 CA CA3017213A patent/CA3017213A1/en active Pending
- 2017-03-10 BR BR112018068354A patent/BR112018068354A2/pt not_active IP Right Cessation
- 2017-03-10 WO PCT/US2017/021951 patent/WO2017156484A1/en active Application Filing
- 2017-03-10 KR KR1020227011695A patent/KR20220047898A/ko not_active Application Discontinuation
- 2017-03-10 CN CN201780027741.0A patent/CN109311984A/zh active Pending
- 2017-03-10 AU AU2017230011A patent/AU2017230011A1/en not_active Abandoned
- 2017-03-10 SG SG11201807820PA patent/SG11201807820PA/en unknown
- 2017-03-10 US US16/083,727 patent/US20190241910A1/en not_active Abandoned
- 2017-03-10 RU RU2018135819A patent/RU2018135819A/ru not_active Application Discontinuation
- 2017-03-10 JP JP2018547876A patent/JP2019509738A/ja active Pending
- 2017-03-10 MX MX2018010924A patent/MX2018010924A/es unknown
-
2018
- 2018-09-05 IL IL261621A patent/IL261621A/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2018135819A (ru) | 2020-04-13 |
KR20180122405A (ko) | 2018-11-12 |
JP2019509738A (ja) | 2019-04-11 |
AU2017230011A1 (en) | 2018-09-27 |
EP3426690A1 (en) | 2019-01-16 |
SG11201807820PA (en) | 2018-10-30 |
CN109311984A (zh) | 2019-02-05 |
KR20220047898A (ko) | 2022-04-19 |
EP3426690A4 (en) | 2019-10-09 |
KR102386029B1 (ko) | 2022-04-13 |
BR112018068354A2 (pt) | 2019-01-15 |
IL261621A (en) | 2018-10-31 |
WO2017156484A1 (en) | 2017-09-14 |
CA3017213A1 (en) | 2017-09-14 |
US20190241910A1 (en) | 2019-08-08 |
RU2018135819A3 (es) | 2020-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018010924A (es) | Células efectoras inmunitarias con edición genómica. | |
JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
MX2019005724A (es) | Conversor de se?ales de tgfbeta. | |
MX2019002725A (es) | Variantes de endonucleasas de asentamiento pd-1, composiciones y metodos de uso. | |
PH12018501378A1 (en) | Compositions and methods for the treatment of hemoglobinopathies | |
MX2019014009A (es) | Metodos mejorados para la elaboracion de terapias celulares adoptivas. | |
EA201891202A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201891201A1 (ru) | Композиции, содержащие бактериальные штаммы | |
MX2017005252A (es) | Metodos para la preparacion de ribosidos. | |
EA201891199A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201790551A1 (ru) | Способы и композиции для ослабления иммунных ответов к пропускающему экзон вирусному трансферному вектору | |
EA201890050A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201890049A1 (ru) | Композиции, содержащие бактериальные штаммы | |
WO2016109546A3 (en) | Methods and compositions for prognosis and treatment of cancers | |
EA201890048A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201890047A1 (ru) | Композиции, содержащие бактериальные штаммы | |
NZ732211A (en) | Combination immunotherapy approach for treatment of cancer | |
MX2017007677A (es) | Inmunomoduladores. | |
SG10201807208RA (en) | Viral resistant cells and uses thereof | |
MX2020010194A (es) | Agente reductor de amoniaco para usarse en el tratamiento de enfermedades asociadas con activacion de celulas estrelladas hepaticas. | |
EP3463399A4 (en) | METHODS OF TREATING AUTOIMMUNE DISEASE USING ALLOGENIC T CELLS | |
MX2017012867A (es) | Composiciones terapeuticas y metodos de uso para tratar el cancer. | |
WO2015106043A3 (en) | Novel synthetic biology-based adcc technology | |
MX2021008225A (es) | Composiciones y metodos para tratamiento de crecimiento celular anormal. | |
PH12017500820A1 (en) | Combination long acting compositions and methods for hepatitis c |